GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma

NCT07138547 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Eliglustat, CD30 target immunotherapy

Sponsor

Chinese PLA General Hospital